170 related articles for article (PubMed ID: 23786291)
1. Non-selective beta-blockers are not associated with serious infections in veterans with cirrhosis.
Bajaj JS; Ratliff SM; Heuman DM; Lapane KL
Aliment Pharmacol Ther; 2013 Aug; 38(4):407-14. PubMed ID: 23786291
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis.
Bajaj JS; Ratliff SM; Heuman DM; Lapane KL
Aliment Pharmacol Ther; 2012 Nov; 36(9):866-74. PubMed ID: 22966967
[TBL] [Abstract][Full Text] [Related]
3. Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers.
Shukla R; Kramer J; Cao Y; Ying J; Tansel A; Walder A; Advani S; El-Serag HB; Kanwal F
Am J Gastroenterol; 2016 Dec; 111(12):1778-1787. PubMed ID: 27670600
[TBL] [Abstract][Full Text] [Related]
4. Nonselective beta-blockers may lead to stage 2 acute kidney injury and waitlist mortality in child class C cirrhosis.
Lai M; Fenton C; Ge J; Rubin J; Lai JC; Cullaro G
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37756037
[TBL] [Abstract][Full Text] [Related]
5. Statin use and infections in Veterans with cirrhosis.
Motzkus-Feagans C; Pakyz AL; Ratliff SM; Bajaj JS; Lapane KL
Aliment Pharmacol Ther; 2013 Sep; 38(6):611-8. PubMed ID: 23889738
[TBL] [Abstract][Full Text] [Related]
6. Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis.
Mohanty A; Tate JP; Garcia-Tsao G
Gastroenterology; 2016 Feb; 150(2):430-40.e1. PubMed ID: 26484707
[TBL] [Abstract][Full Text] [Related]
7. Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation.
Ngwa T; Orman E; Gomez EV; Vuppalanchi R; Kubal C; Chalasani N; Ghabril M
BMC Gastroenterol; 2020 Jan; 20(1):4. PubMed ID: 31906860
[TBL] [Abstract][Full Text] [Related]
8. Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices.
Scheiner B; Parada-Rodriguez D; Bucsics T; Schwabl P; Mandorfer M; Pfisterer N; Riedl F; Sieghart W; Ferlitsch A; Trauner M; Peck-Radosavljevic M; Reiberger T
Scand J Gastroenterol; 2017 Sep; 52(9):1008-1015. PubMed ID: 28532189
[TBL] [Abstract][Full Text] [Related]
9. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites.
Sinha R; Lockman KA; Mallawaarachchi N; Robertson M; Plevris JN; Hayes PC
J Hepatol; 2017 Jul; 67(1):40-46. PubMed ID: 28213164
[TBL] [Abstract][Full Text] [Related]
10. Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis.
Alvarado-Tapias E; Ardevol A; Garcia-Guix M; Montañés R; Pavel O; Cuyas B; Graupera I; Brujats A; Vilades D; Colomo A; Poca M; Torras X; Guarner C; Concepción M; Aracil C; Torres F; Villanueva C
J Hepatol; 2020 Oct; 73(4):829-841. PubMed ID: 32298768
[TBL] [Abstract][Full Text] [Related]
11. Nontumorous Portal Vein Thrombosis in Liver Cirrhosis: Possible Role of β-Blockers.
Giannitrapani L; Granà W; Licata A; Schiavone C; Montalto G; Soresi M
Med Princ Pract; 2018; 27(5):466-471. PubMed ID: 30107378
[TBL] [Abstract][Full Text] [Related]
12. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.
Bossen L; Krag A; Vilstrup H; Watson H; Jepsen P
Hepatology; 2016 Jun; 63(6):1968-76. PubMed ID: 26599983
[TBL] [Abstract][Full Text] [Related]
13. Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites.
Onali S; Kalafateli M; Majumdar A; Westbrook R; O'Beirne J; Leandro G; Patch D; Tsochatzis EA
Liver Int; 2017 Sep; 37(9):1334-1344. PubMed ID: 28296047
[TBL] [Abstract][Full Text] [Related]
14. Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosis.
Labenz C; Nagel M; Toenges G; Kuchen R; Schattenberg JM; Hilscher M; Huber Y; Marquardt JU; Labenz J; Galle PR; Wörns MA
Eur J Intern Med; 2020 Dec; 82():83-89. PubMed ID: 32873457
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte colony-stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease.
Colli A; Fraquelli M; Prati D; Casazza G
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013532. PubMed ID: 37278488
[TBL] [Abstract][Full Text] [Related]
16. The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis.
Sersté T; Njimi H; Degré D; Deltenre P; Schreiber J; Lepida A; Trépo E; Gustot T; Moreno C
Liver Int; 2015 Aug; 35(8):1974-82. PubMed ID: 25611961
[TBL] [Abstract][Full Text] [Related]
17. Predictors of mortality among patients with compensated and decompensated liver cirrhosis: the role of bacterial infections and infection-related acute-on-chronic liver failure.
Sargenti K; Prytz H; Nilsson E; Kalaitzakis E
Scand J Gastroenterol; 2015 Jul; 50(7):875-83. PubMed ID: 25697824
[TBL] [Abstract][Full Text] [Related]
18. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis.
Villanueva C; Albillos A; Genescà J; Garcia-Pagan JC; Brujats A; Calleja JL; Aracil C; Bañares R; Morillas RM; Poca M; Peñas B; Augustin S; Abraldes JG; Alvarado E; Torres F; Bosch J;
J Hepatol; 2021 Sep; 75(3):589-599. PubMed ID: 33905794
[TBL] [Abstract][Full Text] [Related]
19. Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers.
Bang UC; Benfield T; Hyldstrup L; Jensen JE; Bendtsen F
Liver Int; 2016 Sep; 36(9):1304-12. PubMed ID: 26992041
[TBL] [Abstract][Full Text] [Related]
20. Immune changes over time and survival in patients with cirrhosis treated with non-selective beta-blockers: A prospective longitudinal study.
Almenara S; Lozano-Ruiz B; Herrera I; Gimenez P; Miralles C; Bellot P; Rodriguez M; Palazon JM; Tarín F; Sarmiento H; Francés R; Gonzalez-Navajas JM; Pascual S; Zapater P
Biomed Pharmacother; 2023 Jul; 163():114885. PubMed ID: 37201262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
